Robert Tell

This inventor holds 10 USPTO granted patents and 18 published patent applications and 2 EPO patents. Top assignees: Tempus Labs, Inc., Tempus Ai, Inc.. Active years: 2021-2026.

USPTO Granted Patents = 10 (Patent Applications = 18)

% Patents Active = 90.0

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 5.8

ph-index = 3

Forward Citations = 28(Granted Patents)

Company Filing History:

Years Active: 2021-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12584176 - INTEGRATED MACHINE-LEARNING FRAMEWORK TO ESTIMATE HOMOLOGOUS RECOMBINATION DEFICIENCY (2026-03-24),

2. 12536595 - Mobile supplementation, extraction, and analysis of health records (2026-01-27),

3. 12112839 - Data based cancer research and treatment systems and methods (2024-10-08),

4. 11705226 - Data based cancer research and treatment systems and methods (2023-07-18),

5. 11651442 - Mobile supplementation, extraction, and analysis of health records (2023-05-16),

6. 11640859 - Data based cancer research and treatment systems and methods (2023-05-02),

7. 11475981 - Methods and systems for dynamic variant thresholding in a liquid biopsy assay (2022-10-18),

8. 11211147 - Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing (2021-12-28),

9. 11211144 - Methods and systems for refining copy number variation in a liquid biopsy assay (2021-12-28),

10. 10975445 - Integrated machine-learning framework to estimate homologous recombination deficiency (2021-04-13),

Title: The Innovative Contributions of Robert Tell

Introduction

Robert Tell is a prominent inventor based in Chicago, IL, known for his significant contributions to cancer research and treatment technologies. With a total of 10 patents, he has developed innovative methods and systems that enhance the understanding and treatment of cancerous cells.

Latest Patents

Among his latest patents is a groundbreaking method and system for data-based cancer research and treatment. This invention involves storing a set of user application programs that require specific data subsets to perform processes and generate genomic variant characterizations for patients with cancerous cells. The method includes obtaining clinical records data, generating genomic sequencing data for both cancerous and normal cells, and structuring this data for efficient storage and retrieval. Another notable patent focuses on a system for storing user application programs and micro-service programs for multiple patients undergoing cancer treatment. This system optimizes data management and enhances the orchestration of treatment processes.

Career Highlights

Robert Tell has worked with notable companies such as Tempus Labs, Inc. and Tempus AI, Inc. His work in these organizations has been pivotal in advancing cancer treatment methodologies through innovative data management systems.

Collaborations

Throughout his career, Robert has collaborated with esteemed professionals in the field, including Eric Lefkofsky and Shane Colley. These collaborations have further enriched his contributions to cancer research and treatment.

Conclusion

Robert Tell's innovative work in cancer research and treatment systems exemplifies the impact of technology on healthcare. His patents and collaborations continue to pave the way for advancements in the fight against cancer.